
ARS Pharmaceuticals, Inc.: shareholders and insiders
Price
$3.54
November 18, 2026Market cap $352M
What Ploutos Investor adds for ARS Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 5 fiscal years, from 2021
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has risen 38% since Nov 5, 2026, when the 10-Q these figures come from was filed ($2.65 then, $3.65 on Nov 17, 2026). The figures date from before that move.10-Q
Insiders and their shares
Purchases and sales by officers and directors, from their own Form 4 filings.
Reading the newest filings from the SEC. This part fills in on its own in a few seconds.
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- RA Capital Management, L.P.with 3 more personsShare of class11.1%
- Rubric Capital Management LPwith 1 more personShare of class8.06%
- Deerfield Mgmt III, L.P.with 5 more personsShare of class7.75%
- BlackRock, Inc.Share of class5.30%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| RA Capital Management, L.P.with 3 more persons | 11.1% | 10.94M | Oct 1, 2025 | 13D/A | |
| Rubric Capital Management LPwith 1 more person | 8.06% | 8.00M | May 15, 20262 filings since Feb 13, 2026 | 13G/A | |
| Deerfield Mgmt III, L.P.with 5 more persons | 7.75% | 7.61M | Aug 1, 20254 filings since Mar 24, 2025 | 13D/A | |
| BlackRock, Inc. | 5.30% | 5.22M | Jul 27, 20263 filings since Jan 21, 2026 | 13G |
What the holders on a 13D state as their purpose
From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.
RA Capital Management, L.P.11.1%From the filing of Oct 1, 2025
Item 4 is hereby amended and supplemented as follows: On September 29, 2025, the Issuer and certain direct and indirect subsidiaries of the Issuer who may become a party thereto from time to time, as guarantors (the "Guarantors"), and ARS Pharmaceuticals Operations, Inc., a wholly owned subsidiary of the Issuer, as the borrower (the "Borrower" and, collectively with the Guarantors, the "Credit Parties"), entered into a credit agreement (the "Credit Agreement") with RA Capital Agency Services, LLC (as the "Administrative Agent" and as the "Collateral Agent"), and affiliates of OMERS Administration Corporation and RA Capital, as lenders, and such other lenders from time to time party thereto…
From the filing of Oct 1, 2025
Fell to 5% or less (1)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
- Integrated Core Strategies (US) LLC2.50%Jul 14, 202613G/A
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Third Point (Loeb)In the quarter
- Millennium Mgmt (Englander)In the quarter+36%
- Citadel Advisors (Griffin)In the quarter+103%
- Renaissance TechnologiesIn the quarter
- AQR CapitalIn the quarter+173%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Third Point (Loeb) | 1.00M | $4.3M | 0.09% | |
| Millennium Mgmt (Englander) | 3.27M | +36% | $14M | 0.01% |
| Citadel Advisors (Griffin) | 1.08M | +103% | $4.6M | 0.00% |
| Renaissance Technologies | 174.2K | $800.0K | 0.00% | |
| AQR Capital | 97.4K | +173% | $400.0K | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 20.0% of its shares outstanding were held short, -6.5% since the report before.
- Shares held short
- 19.82M
- 20.0%
- Since the report before21.19M on Sep 30, 2026
- -6.5%
- 12.6
- 1.58M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 96%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 6.60M
- Nov 15, 2023: Shares held short 5.94M
- Nov 30, 2023: Shares held short 6.03M
- Dec 15, 2023: Shares held short 6.68M
- Dec 29, 2023: Shares held short 6.97M
- Jan 12, 2024: Shares held short 6.94M
- Jan 31, 2024: Shares held short 4.86M
- Feb 15, 2024: Shares held short 4.86M
- Feb 29, 2024: Shares held short 4.61M
- Mar 15, 2024: Shares held short 4.25M
- Mar 28, 2024: Shares held short 5.50M
- Apr 15, 2024: Shares held short 6.09M
- Apr 30, 2024: Shares held short 6.38M
- May 15, 2024: Shares held short 6.87M
- May 31, 2024: Shares held short 6.82M
- Jun 14, 2024: Shares held short 6.85M
- Jun 28, 2024: Shares held short 6.88M
- Jul 15, 2024: Shares held short 8.74M
- Jul 31, 2024: Shares held short 9.93M
- Aug 15, 2024: Shares held short 12.07M
- Aug 30, 2024: Shares held short 10.96M
- Sep 13, 2024: Shares held short 11.64M
- Sep 30, 2024: Shares held short 11.10M
- Oct 15, 2024: Shares held short 11.92M
- Oct 31, 2024: Shares held short 12.60M
- Nov 15, 2024: Shares held short 13.85M
- Nov 29, 2024: Shares held short 13.63M
- Dec 13, 2024: Shares held short 12.66M
- Dec 31, 2024: Shares held short 13.68M
- Jan 15, 2025: Shares held short 14.81M
- Jan 31, 2025: Shares held short 14.67M
- Feb 14, 2025: Shares held short 16.48M
- Feb 28, 2025: Shares held short 19.00M
- Mar 14, 2025: Shares held short 19.43M
- Mar 31, 2025: Shares held short 17.15M
- Apr 15, 2025: Shares held short 16.46M
- Apr 30, 2025: Shares held short 16.73M
- May 15, 2025: Shares held short 18.23M
- May 30, 2025: Shares held short 17.14M
- Jun 13, 2025: Shares held short 16.58M
- Jun 30, 2025: Shares held short 15.79M
- Jul 15, 2025: Shares held short 14.86M
- Jul 31, 2025: Shares held short 15.34M
- Aug 15, 2025: Shares held short 17.77M
- Aug 29, 2025: Shares held short 21.04M
- Sep 15, 2025: Shares held short 21.58M
- Sep 30, 2025: Shares held short 21.69M
- Oct 15, 2025: Shares held short 18.96M
- Oct 31, 2025: Shares held short 19.76M
- Nov 14, 2025: Shares held short 20.14M
- Nov 28, 2025: Shares held short 20.66M
- Dec 15, 2025: Shares held short 21.59M
- Dec 31, 2025: Shares held short 20.51M
- Jan 15, 2026: Shares held short 20.22M
- Jan 30, 2026: Shares held short 21.40M
- Feb 13, 2026: Shares held short 22.24M
- Feb 27, 2026: Shares held short 22.75M
- Mar 13, 2026: Shares held short 23.72M
- Mar 31, 2026: Shares held short 25.34M
- Apr 15, 2026: Shares held short 26.76M
- Apr 30, 2026: Shares held short 26.19M
- May 15, 2026: Shares held short 25.91M
- May 29, 2026: Shares held short 25.50M
- Jun 15, 2026: Shares held short 23.09M
- Jun 30, 2026: Shares held short 21.73M
- Jul 15, 2026: Shares held short 22.67M
- Jul 31, 2026: Shares held short 21.45M
- Aug 14, 2026: Shares held short 22.95M
- Aug 31, 2026: Shares held short 23.21M
- Sep 15, 2026: Shares held short 23.07M
- Sep 30, 2026: Shares held short 21.19M
- Oct 15, 2026: Shares held short 19.82M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading48.1% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 48.1% of the shares in the reported trades were short sales, against 56.9% in the 14 before.
- Last 14 sessionsOct 29, 2026 – Nov 17, 2026
- 48.1%
- The 14 beforeOct 9, 2026 – Oct 28, 2026
- 56.9%
- Change
- -8.8 pts
- Short sales a dayon average, of 1.05M shares
- 504.3K
- More than atof 3,666 US-listed companies, same days
- 42%
- Median of alleight in ten from 34.6% to 63.7%
- 50.3%
- Short sales
- Oct 9, 2026: Short sales 50.1%
- Oct 12, 2026: Short sales 70.7%
- Oct 13, 2026: Short sales 57.6%
- Oct 14, 2026: Short sales 63.4%
- Oct 15, 2026: Short sales 37%
- Oct 16, 2026: Short sales 62.7%
- Oct 19, 2026: Short sales 71.1%
- Oct 20, 2026: Short sales 68%
- Oct 21, 2026: Short sales 69.1%
- Oct 22, 2026: Short sales 44.4%
- Oct 23, 2026: Short sales 65.6%
- Oct 26, 2026: Short sales 56.3%
- Oct 27, 2026: Short sales 48.2%
- Oct 28, 2026: Short sales 43.9%
- Oct 29, 2026: Short sales 43%
- Oct 30, 2026: Short sales 70%
- Nov 2, 2026: Short sales 58.7%
- Nov 3, 2026: Short sales 38.9%
- Nov 4, 2026: Short sales 37.1%
- Nov 5, 2026: Short sales 50.5%
- Nov 6, 2026: Short sales 30.7%
- Nov 9, 2026: Short sales 44%
- Nov 10, 2026: Short sales 47.2%
- Nov 11, 2026: Short sales 54.1%
- Nov 12, 2026: Short sales 61%
- Nov 13, 2026: Short sales 59.7%
- Nov 16, 2026: Short sales 61.8%
- Nov 17, 2026: Short sales 56.5%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund0.17%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.08%
- IBBiShares Biotechnology ETFWeight in the fund0.04%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.03%
- IWMiShares Russell 2000 ETFWeight in the fund0.02%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.01%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.01%
- VXFVanguard Extended Market Index FundWeight in the fund0.01%
- VHTVanguard Health Care Index FundWeight in the fund0.00%
- ONEQFidelity Nasdaq Composite Index ETFWeight in the fund0.00%
15 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 188
- Q4 2025: Managers 191
- Q1 2026: Managers 204
- Q2 2026: Managers 206
Institutional investors by quarter
The fund managers holding SPRY, quarter by quarter, from Q4 2020 to Q2 2025, 19 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 206 managers held 90.68M shares, worth $727M. During the quarter 38 opened a position, 36 closed one, 72 added and 56 trimmed.
The largest holders, Q2 2026
- Ra Capital ManagementIn the quarter
- Rubric Capital ManagementIn the quarter+6.8%
- Orbimed AdvisorsIn the quarter
- Deerfield ManagementIn the quarter
- BlackRockIn the quarter+6.0%
- Tyro Capital ManagementIn the quarter+50%
- Aberdeen GroupIn the quarter+1.4%
- SR One Capital ManagementIn the quarter
- State StreetIn the quarter+2.4%
- Capital World InvestorsIn the quarter
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Ra Capital Management | 10.86M | $87M | |
| Rubric Capital Management | 8.54M | +6.8% | $68M |
| Orbimed Advisors | 8.29M | $66M | |
| Deerfield Management | 7.50M | $60M | |
| BlackRock | 5.31M | +6.0% | $43M |
| Tyro Capital Management | 4.46M | +50% | $36M |
| Aberdeen Group | 4.17M | +1.4% | $33M |
| SR One Capital Management | 4.01M | $32M | |
| State Street | 3.73M | +2.4% | $30M |
| Capital World Investors | 2.75M | $22M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do ARS Pharmaceuticals's filings show?
Who buys and sells is one part of ARS Pharmaceuticals's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Which well-known managers hold SPRY?
5 of the managers we track held the shares on Sep 30, 2026. The largest position was Millennium Mgmt (Englander)'s, worth $14M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.